Partnering plays a key role in Agennix’s strategy.

Agennix AG is focused on developing novel therapies that have the potential to substantially lengthen and improve the lives of critically ill patients in areas of major unmet medical need.

The Company is focused on pharmaceutical companies and large biotechnology firms with a strong presence in the area of critical care and/or cancer development and commercialization.

For further information on Agennix’s approach to partnering and current opportunities,